Online citations, reference lists, and bibliographies.

The Biopharmaceuticals Field And Algae As Expression Hosts

S. Rosales-Mendoza
Published 2016 · Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Biopharmaceuticals (BFs) are molecules of biological origin and complex composition including vaccines, antibodies, hormones, clotting factors, growth factors, and cytokines that are used in addressing a variety of conditions. Despite of decades having recombinant DNA technology and sustained pharmaceutical industry development, the world faces a serious need for accessible biopharmaceuticals. Access to vaccines and other therapeutics is limited in developing countries where public resources are not sufficient to make them accessible to cope with the costs associated to their production, distribution through cold chain, and safe parenteral administration. The production of biosimilars and biobetters is opening an opportunity to improve efficacy and save resources in this field. In parallel, biotechnological alternatives for BFs production are gaining interest. In particular, genetically engineered photosynthetic organisms have been explored as biofactories and even delivery vehicles. In particular, algae species have been proposed as a low cost and convenient platform for the production of BFs. This chapter serves as an introduction to this book by presenting a brief overview of the BFs field as well as the general features of algae species that make them attractive as BFs biofactories.
This paper references
10.1007/s00253-006-0465-8
Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems
K. Terpe (2006)
10.3389/fmicb.2015.01376
In Metabolic Engineering of Eukaryotic Microalgae: Potential and Challenges Come with Great Diversity
Javier A. Gimpel (2015)
10.5639/GABIJ.2012.0103-4.036
Saving money in the European healthcare systems with biosimilars
Robert Haustein (2012)
10.1023/B:JAPH.0000004298.89183.e5
Stable expression of hepatitis B surface antigen gene in Dunaliella salina (Chlorophyta)
Degui Geng (2004)
10.1016/j.tibtech.2015.11.007
Food-Grade Organisms as Vaccine Biofactories and Oral Delivery Vehicles.
S. Rosales-Mendoza (2016)
10.1007/s00253-010-2639-7
Development of a stepwise aeration control strategy for efficient docosahexaenoic acid production by Schizochytrium sp.
Lu-jing Ren (2010)
10.1104/pp.104.041491
Chlamydomonas and Arabidopsis. A Dynamic Duo1
Benjamin L. Gutman (2004)
10.1016/j.biortech.2014.10.139
Microalgal drying and cell disruption--recent advances.
K. Show (2015)
10.1111/pbi.12428
Large-scale production of pharmaceutical proteins in plant cell culture-the Protalix experience.
Yoram Tekoah (2015)
10.1016/J.TIBTECH.2004.06.003
When biotech proteins go off-patent.
H. Schellekens (2004)
10.1146/annurev.ge.29.120195.001233
Chlamydomonas reinhardtii as the photosynthetic yeast.
J. Rochaix (1995)
10.3748/wjg.v21.i6.1728
Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.
F. Rencz (2015)
10.1111/pbi.12475
Plant‐produced candidate countermeasures against emerging and reemerging infections and bioterror agents
S. Streatfield (2015)
10.1371/journal.pone.0061790
Vaccination against Influenza with Recombinant Hemagglutinin Expressed by Schizochytrium sp. Confers Protective Immunity
Anne-Cécile V. Bayne (2013)
10.1016/j.sbi.2014.03.006
Better and faster: improvements and optimization for mammalian recombinant protein production.
S. Almo (2014)
10.1128/EC.00326-10
Do Red and Green Make Brown?: Perspectives on Plastid Acquisitions within Chromalveolates
R. Dorrell (2011)
10.1111/jphp.12353
Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?
R. M. Bill (2015)
10.1371/journal.pone.0133535
The Corn Smut (‘Huitlacoche’) as a New Platform for Oral Vaccines
Margarita Juárez-Montiel (2015)
10.1007/s00253-013-5226-x
Ice recrystallization inhibition mediated by a nuclear-expressed and -secreted recombinant ice-binding protein in the microalga Chlamydomonas reinhardtii
K. Lauersen (2013)
10.1046/J.1529-8817.1999.3520215.X
COMMERCIAL DEVELOPMENTS IN MICROALGAL BIOTECHNOLOGY
K. Apt (1999)
10.1007/978-1-4020-8480-5_17
Oddities and Curiosities in the Algal World
L. Barsanti (2008)
10.1111/tpj.12781
Establishing Chlamydomonas reinhardtii as an industrial biotechnology host
Mark A. Scaife (2015)
Production of Natural Biopharmaceuticals from the Microalgae Living in the Dead Sea
Sadeq Emeish (2013)
10.1007/s11033-008-9333-1
Improvement of efficiency of genetic transformation for Dunaliella salina by glass beads method
Shuying Feng (2008)
10.1078/1434-4610-00068
Molecular phylogeny and taxonomic revision of Chlamydomonas (Chlorophyta). I. Emendation of Chlamydomonas Ehrenberg and Chloromonas Gobi, and description of Oogamochlamys gen. nov. and Lobochlamys gen. nov.
T. Pröschold (2001)
10.1007/BF02186067
Microalgal feeds for aquaculture
R. Gladue (2004)
10.1038/nbt.2060
What's fueling the biotech engine--2010 to 2011.
S. Aggarwal (2011)
10.1016/S1389-0344(03)00076-5
Commercial development of microalgal biotechnology: from the test tube to the marketplace.
M. Olaizola (2003)
10.1016/j.yrtph.2015.12.013
Biosimilars: A consideration of the regulations in the United States and European union.
J. Daller (2016)
10.1136/rmdopen-2014-000040
The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries
A. Finckh (2015)
10.1002/bit.25517
Algal productivity modeling: A step toward accurate assessments of full‐scale algal cultivation
Q. Béchet (2015)
10.1016/S1470-2045(15)70088-4
First biosimilar drug approved in the USA.
Talha Khan Burki (2015)
10.1186/1475-2859-11-126
An engineered diatom acting like a plasma cell secreting human IgG antibodies with high efficiency
F. Hempel (2012)
10.1016/j.jbiotec.2015.05.001
Investigating the dynamics of recombinant protein secretion from a microalgal host.
K. Lauersen (2015)
10.1016/j.biotechadv.2015.10.015
The art of CHO cell engineering: A comprehensive retrospect and future perspectives.
Simon Fischer (2015)
10.1007/978-3-642-47774-4_26
Über die Geschwindigkeit der photochemischen Kohlensäurezersetzung in lebenden Zellen. II
O. Warburg
10.1007/s40259-015-0133-6
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
W. Strohl (2015)
10.1007/s00705-013-1856-7
Preparation of transgenic Dunaliella salina for immunization against white spot syndrome virus in crayfish
Shuying Feng (2013)
10.1038/nbt1104-1357
How similar do 'biosimilars' need to be?
H. Schellekens (2004)
The Cost Savings Potential of Biosimilar Drugs in the United States
A. Mulcahy (2014)
10.1016/j.biortech.2014.11.040
Extremophilic micro-algae and their potential contribution in biotechnology.
P. Varshney (2015)
10.1038/nbt1109-987
What's fueling the biotech engine—2008
S. Aggarwal (2009)
Cultivo de cepas de Dunaliella salina (Teodoresco 1905) en diferentes medios bajo condiciones de laboratorio
Oscar Parra (1996)
10.1007/s00299-011-1186-8
Chlamydomonas reinhardtii as a viable platform for the production of recombinant proteins: current status and perspectives
S. Rosales-Mendoza (2011)
10.1007/BF02172403
Stable nuclear transformation of the diatomPhaeodactylum tricornutum
K. Apt (2005)
10.1007/BF02186327
Recent advances in microalgal bioscience in Japan, with special reference to utilization of biomass and metabolites: a review
K. Yamaguchi (2004)
10.2527/jas.2013-7024
Dose-response of supplementing marine algae (Schizochytrium spp.) on production performance, fatty acid profiles, and wool parameters of growing lambs.
Sarah J Meale (2014)
10.1016/j.copbio.2015.08.012
Manipulating the glycosylation pathway in bacterial and lower eukaryotes for production of therapeutic proteins.
Diana Chinyere Anyaogu (2015)
10.1371/journal.pone.0028424
Algae as Protein Factories: Expression of a Human Antibody and the Respective Antigen in the Diatom Phaeodactylum tricornutum
F. Hempel (2011)
10.1016/j.biortech.2010.06.159
Cultivation, photobioreactor design and harvesting of microalgae for biodiesel production: a critical review.
C. Chen (2011)
10.1111/pbi.12366
Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease.
Yoseph Shaaltiel (2015)
10.2307/2992511
Diatoms: Biology and Morphology of the Genera
F. E. Round (1990)
10.1016/S0958-1669(02)00354-3
Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics.
S. A. Kellermann (2002)
10.1007/BF02186066
Heterotrophic production of long chain omega-3 fatty acids utilizing algae and algae-like microorganisms
W. Barclay (2004)
10.1093/jxb/erv426
Biotechnological exploitation of microalgae.
Doris Gangl (2015)
10.1007/s11120-004-2216-y
The Chlamydomonas genome reveals its secrets: chaperone genes and the potential roles of their gene products in the chloroplast
M. Schroda (2004)
Plant organelles contain distinct peptidylprolyl cis,trans-isomerases.
A. Breiman (1992)
10.1126/SCIENCE.278.5345.1954
Protein disulfide isomerase as a regulator of chloroplast translational activation.
J. Kim (1997)
10.1111/pbi.12401
Moss‐made pharmaceuticals: from bench to bedside
R. Reski (2015)
10.1007/S10267-006-0362-0
Taxonomic rearrangement of the genus Schizochytrium sensu lato based on morphology, chemotaxonomic characteristics, and 18S rRNA gene phylogeny (Thraustochytriaceae, Labyrinthulomycetes): emendation for Schizochytrium and erection of Aurantiochytrium and Oblongichytrium gen. nov.
Rinka Yokoyama (2007)
10.1016/0167-7799(90)90152-N
The biotechnology of cultivating the halotolerant algaDunaliella
A. Ben-Amotz (1990)
10.4161/mabs.3.2.14785
Biosimilar, biobetter and next generation therapeutic antibodies
A. Beck (2011)
10.1263/JBB.99.303
Solubilization and refolding of bacterial inclusion body proteins.
S. Singh (2005)
10.1016/S1389-0344(03)00074-1
Realizing the promises of marine biotechnology.
Esther E. M. Luiten (2003)
10.1126/science.2897716
Chloroplast transformation in Chlamydomonas with high velocity microprojectiles.
J. Boynton (1988)
10.1016/j.ijpharm.2011.12.039
Therapeutic antibodies: market considerations, disease targets and bioprocessing.
J. Elvin (2013)
10.1371/journal.pone.0099677
Evolution of the Global Burden of Viral Infections from Unsafe Medical Injections, 2000–2010
J. Pépin (2014)
10.1016/j.biotechadv.2011.09.011
Production of recombinant proteins by yeast cells.
E. Çelik (2012)
10.1002/bit.25357
Production of recombinant proteins in microalgae at pilot greenhouse scale
Javier A. Gimpel (2015)
10.1080/19420862.2015.1078054
Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori)
Minoru Tada (2015)
10.3390/v7082819
Public Acceptance of Plant Biotechnology and GM Crops
J. M. Lucht (2015)
10.1371/journal.pone.0043349
Robust Expression and Secretion of Xylanase1 in Chlamydomonas reinhardtii by Fusion to a Selection Gene and Processing with the FMDV 2A Peptide
B. Rasala (2012)
10.1104/pp.24.1.120
THE CHEMICAL COMPOSITION OF CHLORELLA; EFFECT OF ENVIRONMENTAL CONDITIONS.
H. A. Spoehr (1949)
10.1073/pnas.1520698112
Core Concepts: Biosimilars
S. Ornes (2015)
10.1016/j.drudis.2013.11.008
Recombinant protein production in bacterial hosts.
T. Overton (2014)



Semantic Scholar Logo Some data provided by SemanticScholar